1. Home
  2. SSKN vs BCDA Comparison

SSKN vs BCDA Comparison

Compare SSKN & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SSKN
  • BCDA
  • Stock Information
  • Founded
  • SSKN 1989
  • BCDA N/A
  • Country
  • SSKN United States
  • BCDA United States
  • Employees
  • SSKN N/A
  • BCDA N/A
  • Industry
  • SSKN Medical/Dental Instruments
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • SSKN Health Care
  • BCDA Health Care
  • Exchange
  • SSKN Nasdaq
  • BCDA Nasdaq
  • Market Cap
  • SSKN 10.6M
  • BCDA 9.4M
  • IPO Year
  • SSKN 2005
  • BCDA N/A
  • Fundamental
  • Price
  • SSKN $2.59
  • BCDA $2.01
  • Analyst Decision
  • SSKN Strong Buy
  • BCDA Strong Buy
  • Analyst Count
  • SSKN 1
  • BCDA 1
  • Target Price
  • SSKN $6.00
  • BCDA $25.00
  • AVG Volume (30 Days)
  • SSKN 3.2K
  • BCDA 95.4K
  • Earning Date
  • SSKN 05-14-2025
  • BCDA 05-13-2025
  • Dividend Yield
  • SSKN N/A
  • BCDA N/A
  • EPS Growth
  • SSKN N/A
  • BCDA N/A
  • EPS
  • SSKN N/A
  • BCDA N/A
  • Revenue
  • SSKN $33,562,000.00
  • BCDA $58,000.00
  • Revenue This Year
  • SSKN $8.57
  • BCDA N/A
  • Revenue Next Year
  • SSKN $9.44
  • BCDA N/A
  • P/E Ratio
  • SSKN N/A
  • BCDA N/A
  • Revenue Growth
  • SSKN 0.61
  • BCDA N/A
  • 52 Week Low
  • SSKN $2.51
  • BCDA $1.63
  • 52 Week High
  • SSKN $5.90
  • BCDA $6.15
  • Technical
  • Relative Strength Index (RSI)
  • SSKN 45.08
  • BCDA 36.56
  • Support Level
  • SSKN $2.54
  • BCDA $2.45
  • Resistance Level
  • SSKN $2.72
  • BCDA $2.95
  • Average True Range (ATR)
  • SSKN 0.13
  • BCDA 0.24
  • MACD
  • SSKN -0.00
  • BCDA -0.07
  • Stochastic Oscillator
  • SSKN 37.52
  • BCDA 6.00

About SSKN Strata Skin Sciences Inc.

Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: